Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific/Medinol dispute

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific wins the latest round in a long-running patent dispute with stent maker Medinol May 5 when a World Intellectual Property Organization arbitration panel ruled that Boston Scientific's Liberté and Taxus Liberté stents do not infringe Medinol patents. Medinol requested the arbitration in 2006 (1"The Gray Sheet" Feb. 27, 2006, In Brief). In 2005, Boston Scientific paid $750 million to settle infringement claims related to its Express and first-generation Taxus stents. Under the settlement, Medinol cannot sue Boston Scientific again for patent infringement, but can through arbitration seek royalties for past and future sales of other stents through 2017. Medinol has the right to appeal the most recent arbitration ruling to another WIPO panel
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT026094

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel